23.40
Anaptysbio Inc stock is traded at $23.40, with a volume of 472.65K.
It is up +0.86% in the last 24 hours and up +16.36% over the past month.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
See More
Previous Close:
$23.20
Open:
$23.2
24h Volume:
472.65K
Relative Volume:
0.99
Market Cap:
$655.13M
Revenue:
$17.16M
Net Income/Loss:
$-163.62M
P/E Ratio:
-3.8487
EPS:
-6.08
Net Cash Flow:
$-121.61M
1W Performance:
+6.85%
1M Performance:
+16.36%
6M Performance:
+32.13%
1Y Performance:
-38.90%
Anaptysbio Inc Stock (ANAB) Company Profile
Name
Anaptysbio Inc
Sector
Industry
Phone
858-362-6295
Address
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ANAB
Anaptysbio Inc
|
23.40 | 637.22M | 17.16M | -163.62M | -121.61M | -6.08 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
Feb-04-25 | Initiated | Wolfe Research | Outperform |
Dec-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
Dec-02-24 | Downgrade | BTIG Research | Buy → Neutral |
Jul-22-24 | Initiated | H.C. Wainwright | Buy |
Jul-19-24 | Upgrade | JP Morgan | Neutral → Overweight |
Apr-16-24 | Initiated | Leerink Partners | Outperform |
Apr-11-24 | Initiated | Wells Fargo | Overweight |
Mar-12-24 | Upgrade | Wedbush | Neutral → Outperform |
Feb-26-24 | Initiated | BTIG Research | Buy |
Feb-21-24 | Initiated | Stifel | Buy |
Feb-16-24 | Initiated | Piper Sandler | Overweight |
May-22-23 | Upgrade | JP Morgan | Underweight → Neutral |
May-18-23 | Initiated | TD Cowen | Outperform |
Jan-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
Nov-01-22 | Upgrade | Guggenheim | Neutral → Buy |
Sep-19-22 | Resumed | H.C. Wainwright | Buy |
Sep-13-22 | Downgrade | Truist | Buy → Hold |
Sep-01-22 | Initiated | Raymond James | Outperform |
Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
Jun-22-21 | Initiated | H.C. Wainwright | Buy |
May-21-21 | Initiated | UBS | Neutral |
Mar-16-21 | Upgrade | Truist | Hold → Buy |
Mar-09-21 | Downgrade | Wedbush | Outperform → Neutral |
Mar-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
Feb-11-21 | Upgrade | JP Morgan | Underweight → Overweight |
Oct-27-20 | Upgrade | Wedbush | Neutral → Outperform |
Oct-14-20 | Upgrade | Guggenheim | Neutral → Buy |
Nov-08-19 | Downgrade | JP Morgan | Overweight → Underweight |
Nov-08-19 | Downgrade | Jefferies | Buy → Hold |
Nov-08-19 | Downgrade | SunTrust | Buy → Hold |
Nov-08-19 | Downgrade | Wedbush | Outperform → Neutral |
Jun-21-19 | Downgrade | Credit Suisse | Outperform → Neutral |
Jun-21-19 | Downgrade | Stifel | Buy → Hold |
Dec-20-18 | Initiated | H.C. Wainwright | Buy |
Nov-21-18 | Initiated | JP Morgan | Overweight |
Jul-19-18 | Initiated | Credit Suisse | Outperform |
Apr-04-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Mar-27-18 | Reiterated | Stifel | Buy |
Mar-06-18 | Reiterated | Stifel | Buy |
Feb-15-18 | Reiterated | SunTrust | Buy |
Jan-23-18 | Reiterated | Credit Suisse | Outperform |
Nov-15-17 | Initiated | SunTrust | Buy |
Nov-09-17 | Initiated | Jefferies | Buy |
Oct-11-17 | Reiterated | RBC Capital Mkts | Outperform |
Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
View All
Anaptysbio Inc Stock (ANAB) Latest News
AnaptysBio, Inc. $ANAB Shares Acquired by Granahan Investment Management LLC - MarketBeat
Exome Asset Management LLC Acquires New Position in AnaptysBio, Inc. $ANAB - MarketBeat
PDT Partners LLC Makes New $828,000 Investment in AnaptysBio, Inc. $ANAB - MarketBeat
Trexquant Investment LP Grows Stake in AnaptysBio, Inc. $ANAB - MarketBeat
Does AnaptysBio Inc. have pricing powerJuly 2025 News Drivers & Low Risk Entry Point Guides - Lancaster City Council
AnaptysBio (NASDAQ:ANAB) Stock Price Up 5.1%What's Next? - MarketBeat
Rafferty Asset Management LLC Trims Holdings in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio Inc. Breakout Confirmed by Volume MetricsJuly 2025 Pullbacks & Weekly High Return Forecasts - beatles.ru
AnaptysBio, Inc. $ANAB Position Increased by Palo Alto Investors LP - MarketBeat
683 Capital Management LLC Takes $3.64 Million Position in AnaptysBio, Inc. $ANAB - MarketBeat
First Light Asset Management LLC Has $86.14 Million Stock Holdings in AnaptysBio, Inc. $ANAB - MarketBeat
Nuveen LLC Invests $1.04 Million in AnaptysBio, Inc. $ANAB - MarketBeat
Earnings Recap: Will AnaptysBio Inc. outperform tech stocksJuly 2025 Price Swings & Daily Momentum Trading Reports - خودرو بانک
Will AnaptysBio Inc. benefit from geopolitical trendsJuly 2025 Retail & Weekly Return Optimization Alerts - خودرو بانک
What recovery options are there for AnaptysBio Inc.2025 Year in Review & Stock Portfolio Risk Control - Newser
Technical signs of recovery in AnaptysBio Inc.2025 Market Sentiment & Free Real-Time Market Sentiment Alerts - Newser
Will AnaptysBio Inc. outperform its industry peersJuly 2025 Weekly Recap & Weekly Watchlist of Top Performers - خودرو بانک
How sensitive is AnaptysBio Inc. to inflationBond Market & Weekly High Return Forecasts - خودرو بانک
Will AnaptysBio Inc. benefit from rising consumer demand2025 EndofYear Setup & Expert Verified Stock Movement Alerts - خودرو بانک
Trend analysis for AnaptysBio Inc. this weekJuly 2025 Volume & Low Drawdown Investment Ideas - Newser
Will AnaptysBio Inc. continue its uptrendJuly 2025 Closing Moves & High Accuracy Swing Entry Alerts - Newser
using ichimoku cloud for anaptysbio inc. technicalsWeekly Investment Report & Verified Stock Trade Ideas - Newser
Visualizing AnaptysBio Inc. stock with heatmaps2025 Fundamental Recap & AI Driven Stock Reports - Newser
AnaptysBio Inc. Outperforms Peers on Volume MetricsJuly 2025 Chart Watch & Verified Short-Term Plans - beatles.ru
AnaptysBio, Inc. $ANAB Position Trimmed by Charles Schwab Investment Management Inc. - MarketBeat
What machine learning models say about AnaptysBio Inc.2025 Stock Rankings & Free Verified High Yield Trade Plans - Newser
How to recover losses in AnaptysBio Inc. stock2025 Winners & Losers & Verified Technical Signals - Newser
Is AnaptysBio Inc. trading at a discount2025 Trading Volume Trends & Trade Opportunity Analysis Reports - خودرو بانک
Can swing trading help recover from AnaptysBio Inc. lossesJuly 2025 Catalysts & Safe Capital Investment Plans - Newser
Using Ichimoku Cloud for AnaptysBio Inc. technicalsMarket Trend Report & Free Real-Time Volume Trigger Notifications - Newser
Will AnaptysBio Inc. price bounce be sustainableJuly 2025 Levels & Real-Time Stock Movement Alerts - Newser
AnaptysBio Inc.’s volatility index tracking explainedDollar Strength & Stepwise Entry and Exit Trade Signals - Newser
Can trapped investors hope for a rebound in AnaptysBio Inc.2025 Fundamental Recap & Fast Gain Swing Trade Alerts - Newser
Can momentum traders help lift AnaptysBio Inc.July 2025 Opening Moves & Stock Market Timing Techniques - Newser
Can AnaptysBio Inc. ride the EV waveMarket Sentiment Review & Real-Time Volume Spike Alerts - خودرو بانک
Chart based analysis of AnaptysBio Inc. trends2025 Bull vs Bear & Verified Entry Point Signals - Newser
Is AnaptysBio Inc. a cyclical or defensive stockJuly 2025 Technicals & Fast Entry and Exit Trade Plans - خودرو بانک
Historical volatility pattern of AnaptysBio Inc. visualizedJuly 2025 Recap & Expert Approved Momentum Trade Ideas - Newser
What does recent volatility data suggest for AnaptysBio Inc.Wall Street Watch & Intraday High Probability Alerts - Newser
Anaptysbio Inc Stock (ANAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):